COMPOUND PROFILE / PEPTIDES & ANALOGUES
PE-22-28.
Research draftPE-22-28 is a shortened spadin-related experimental peptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
PE-22-28 is a shortened spadin-related experimental peptide.
Mechanism
It inhibits the TREK-1 potassium channel in laboratory systems.
Human research
A therapeutic human clinical evidence base was not established.
Preclinical & other research
Mouse and cell experiments investigated antidepressant-like responses and synaptic measures.
Safety & unknowns
Behavioural results in mice do not establish antidepressant efficacy or safety in people.
Regulatory status
Preclinical compound, not an established depression treatment.
Reported use & evidence
The supplied PE-22-28 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.